Search
Search
Close this search box.

Review of Federal Cannabis Scheduling to be Completed ‘This Year’, As Reform Leaders Offer Cautious Optimism 

The US Secretary for the Department of Health and Human Services (HHS) Xavier Becerra has said he believes the hotly anticipated cannabis scheduling review will be completed ‘this year’.

Last week Mr Becarra gave the first rough timeline of when the crucial cannabis administrative review of federal marijuana scheduling will be completed.

After President Biden announced the review, alongside mass pardons for those charged with minor federal cannabis offences last October, there has been little in the way of updates regarding its progress.

Speaking to Marijuana Moment at press briefing in Sacramento on Thursday, Mr Becerra said: “What I can tell you is that the president instructed us at HHS—FDA in particular—to take a look at how we treat marijuana to see if we can update our review of marijuana as a drug and how we can make sure how we treat it going forward on the federal level.

“Places like California have already changed the laws, the federal government has not, and so we’ve been instructed and we’re underway with that review as we speak.”

Three co-chairs of the Congressional Cannabis Caucus have now responded positively to the news, including Rep. Earl Blumenauer, Rep. Dave Joyce and Rep. Barbara Lee, the latter of which said: “Federal descheduling is long overdue. We’ve been pushing the Biden administration to take bold steps to end the war on drugs, and I’m hopeful they will.”

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?